Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Erythrodermic psoriasis (EP) is a severe and complex form of psoriasis. While risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in patients with moderate-to-severe plaque psoriasis, its effectiveness in patients with EP remains less explored. The literature contains several...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini
Format: Article
Language:English
Published: PAGEPress Publications 2025-07-01
Series:Dermatology Reports
Subjects:
Psoriasis
risankizumab
erythrodermic psoriasis
safety
efficacy
Online Access:https://www.pagepress.org/journals/dr/article/view/10379
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pagepress.org/journals/dr/article/view/10379

Similar Items